Whalesbook
Viyash Scientific Reports First Post-Merger Results Amidst Valuation Scrutiny
The newly formed Viyash Scientific, the result of the significant merger between SeQuent Scientific and Viyash Lifesciences, has unveiled its inaugural financial results for the December quarter. The report showcases robust top-line growth and a substantial EBITDA expansion, signaling that the anticipated synergies from the ₹8,000 crore consolidation are beginning to materialize. However, the company's debut performance is met with caution due to profit volatility and a commanding market valuation that is drawing increased investor scrutiny.
Synergy Realization Validates Merger Thesis
The December quarter saw Viyash Scientific post a consolidated revenue of ₹858 crore, marking an 11% increase year-over-year. More impressively, EBITDA surged by 64% to ₹185 crore compared to the same period last year, indicating effective cost management and operational integration post-merger [cite: Source A, 9]. Net profit for the quarter stood at ₹48 crore, an increase of 15% year-over-year, according to company disclosures [cite: Source A, 9]. Dr. Hari Babu Bodepudi, Managing Director and Group CEO, attributed this performance to the cohesive "one team" approach and strategic actions taken post-integration, emphasizing new product introductions, cost improvements, and cross-business unit synergies [cite: Source A, 9]. The company's management highlighted a strong balance sheet and market position, positioning it to capture future market opportunities over the next three to five years.
Integrated Model Faces Market Test
The merger strategically combined SeQuent's established animal health portfolio with Viyash's expertise in human health Active Pharmaceutical Ingredients (APIs) and formulations, creating what is touted as India's largest animal health company. This integrated model aims to leverage R&D, manufacturing, and commercial synergies across both human and animal health segments. The Indian animal health market is projected for robust growth, with an expected CAGR of 11.5% to reach $2.0 billion by 2035. Similarly, the Indian API market is poised to grow at a 7.74% CAGR, reaching $22.18 billion by 2031, driven by government support and global supply chain diversification. While these sector tailwinds provide a strong foundation, Viyash Scientific's specific performance metrics are under the microscope as it navigates these expanding markets.
The Forensic Bear Case: Profit Volatility and Stretched Valuations
Despite the headline revenue and EBITDA figures, a deeper analysis reveals concerning trends in profitability and valuation. Reports indicate that while operating margins reached record highs of 20.46% in Q3 FY26, the consolidated net profit declined quarter-on-quarter and year-on-year, contrary to the company's reported net profit increase. Specifically, some analyses highlight a year-on-year decline from Q3 FY25's ₹44.61 crore to ₹38.44 crore in Q3 FY26, raising questions about earnings sustainability. This profit volatility, coupled with the company's current market capitalization of approximately ₹9,121 crore and a trailing twelve-month P/E ratio of 206x, suggests a highly stretched valuation. For context, major pharmaceutical players like Sun Pharma trade at a P/E of 37.4 and Dr. Reddy's Laboratories at 18.7. The market reaction reflected these concerns, with Viyash Scientific's stock declining 3.92% following the results announcement on February 6, 2026. Analyst sentiment remains mixed, with a 'Hold' rating from MarketsMOJO, preceded by a downgrade to 'Sell' in mid-January 2026. Dr. Hari Babu Bodepudi, the CEO, brings extensive experience from leading global pharmaceutical operations, but the company's ability to translate revenue growth into consistent bottom-line performance and justify its premium valuation remains a key challenge. Efforts to improve the net debt to LTM EBITDA ratio to 0.7x are noted, a positive step from 1.4x in Q2 FY25.
Future Outlook
Management expresses optimism about capitalizing on market opportunities over the next three to five years, citing a strong balance sheet and market position. The company expects continued benefits from R&D, manufacturing, and front-end synergies stemming from the merger. Viyash Scientific is strategically positioned within two high-growth sectors: animal health and pharmaceuticals. Continued focus on integrating operations, launching new products, and managing costs will be crucial for achieving sustained profitability and navigating the competitive Indian and global pharmaceutical landscapes. The company's ability to manage its high valuation premium against a backdrop of profit volatility will be closely monitored by investors.